The relationship of preoperative and postoperative serumCEA and CA 19-9 levels with tumor localization, stage andoverall survival in patients with colorectal cancer

Aim: To evaluate the prognostic value of pre/postoperative serum levels of Carcinoembryonic antigen (CEA), Carbohydrate antigen19-9 (CA 19-9), and their relationship with primary localization and stage of colorectal cancer (CRC) patients.Materials and Methods: 255 patients who underwent curative or palliative surgery with the diagnosis of CRC between 2015 and 2020were included in the study. The patients were divided into groups as right colon tumor and left colon tumor based on the region ofthe primary tumor. Baseline data on age, sex, location of primary tumor, disease stage, histological differentiation, BRAF and RASmutation situations and serum CEA and CA 19-9 levels were recorded before and after surgery. Individuals were followed for at leastsixty months or until they died. Overall survival (OS) and Disease Free Survival (DFS) rates were estimated using the Kaplan–Meiermethod. Results: 103 patients had right sided (41.4%) and 152 patients (59.6%) had left sided CRC. Most of the patients were in the early stage(71%). DFS and OS patients with left colon tumors were longer than the right. [(DFS, 32.18 (6-60) vs. 34.25 (6-60) months, p=0.332)and (OS, 41.16 (6-60) vs. 49.05 (11-60) months, p=0.002]. An assessment of the prognosis showed that the OS was significantlyworse in the patients with a high CEA level (p=0.001) and in the patients with a high CA 19-9 level (p=0.001). In multivariate analysis,normal serum CA 19-9 levels (p=0.002), RAS wild type tumor (p

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics. CA Cancer J Clin 2017;67:177-93.
3. Nordlinger B. European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009;20:985-92.
4. Saleh K, Khalife-Saleh N, Kourie HR, et al. How and when adjuvant treatment should be intensified in stage III colorectal cancers? Future Oncol 2017;13:1999- 2006.
5. Al-Hajeili M, Marshall JL, Smaglo BG. Neoadjuvant treatment for surgically resectable metastatic colorectal cancer. Oncology 2016;30.
6. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol 2002;20:1499-505.
7. Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 2017;70:87-98.
8. Karatas. F, Sahin S. Rekürren Kolorektal Kanserli Hastalarda Primer Tümör Lokalizasyonu Ve Sağkalim Arasindaki İlişki The relationship Between Primary Tumor Localization and Survival in Patients with Recurrent Colorectal Cancer. Bozok Tıp Dergisi 2019;9:11-5.
9. Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer. Hepato-gastroenterology 1999;46:905-8.
10. Uehara M, Manaka D, Baba S, et al. Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer. Gan to Kagaku Ryoho 2007;34:1413.
11. Jia J, Zhang P, Gou M, et al. The role of serum Cea and Ca19-9 in efficacy evaluations and progressionfree survival predictions for patients treated with cetuximab combined with Folfox4 or Folfiri as a firstline treatment for advanced colorectal cancer. Dis markers 2019;1.
12. Zhang L-N, OuYang P-Y, Xiao W-W, et al. Elevated CA19-9 as the most significant prognostic factor in locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Medicine 2015;94.
13. Shibutani M, Maeda K, Nagahara H, et al. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. Anticancer Res 2014;34:3753-8.
14. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101:403-8.
15. Mik M, Berut M, Dziki L, et al. Right-and left-sided colon cancer–clinical and pathological differences of the disease entity in one organ. Archives of medical science: Arc Med Sci 2017;13:157.
16. Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World journal of gastroenterology: World J Gastroenterol 2012;18:5171.
17. Adelstein B-A, Dobbins TA, Harris CA, et al. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 2011;47:1343-54.
18. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683-91.
19. Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget 2017;8:86356.
20. Aljehani MA, Morgan JW, Guthrie LA, et al. Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer. JAMA surg 2018;153:60-7.
21. Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015;148:88-99.
22. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32.
23. Breivik J, Lothe RA, Meling GI, et al. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer. 1997;74:664-9.
24. Chen C-C, Yang S-H, Lin J-K, et al. Is it reasonable to add preoperative serum level of CEA and CA19- 9 to staging for colorectal cancer? J Surg Res 2005;124:169-74.
25. Diez M, Cerdán F, Pollan M, et al. Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma. Anticancer Res 1994;14:2819-25.
26. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointestinal Oncol 2012;3:105.
27. Woo J, Kim J, Park I, et al. Perioperative serum carcinoembryonic antigen ratio is a prognostic indicator in patients with stage II colorectal cancer. Ann Coloproctol 2018;34:4.
28. Qin Q, Yang L, Sun Y-K, et al. Comparison of 627 patients with right-and left-sided colon cancer in China: Differences in clinicopathology, recurrence, and survival. Chronic Dis Trans Med 2017;3:51-9.
29. Nakagawa-Senda H, Hori M, Matsuda T, et al. Prognostic impact of tumor location in colon cancer: the Monitoring of Cancer Incidence in Japan (MCIJ) project. BMC cancer 2019;19:1-9
30. Ahmed S, Leis A, Fields A, et al. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal Cancer: results from a large population-based cohort study. Cancer 2014;120:683- 91.
31. Vauthey J-N, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013;258.
32. Ducreux M, Chamseddine A, Laurent-Puig P, et al. Molecular targeted therapy of BRAFmutant colorectal cancer. Ther Adv Med Oncol 2019;11:1758835919856494.